- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vyome Holdings Inc (HIND)
Vyome Holdings Inc stock price live, this page displays NASDAQ HIND stock exchange data. View the HIND premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vyome Holdings Inc real time stock price chart below.
What Is the Vyome Holdings Inc Stock Price Today?
The Vyome Holdings Inc stock price today is 2.115.
What Is the Stock Symbol for Vyome Holdings Inc?
The stock symbol for Vyome Holdings Inc is "HIND."
What Stock Exchange Does Vyome Holdings Inc Trade On?
Vyome Holdings Inc is listed and trades on the NASDAQ stock exchange.
Is Vyome Holdings Inc a Good Stock to Buy?
Determining whether Vyome Holdings Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HIND quote. (ISIN: US92943X1046)
What Is the Vyome Holdings Inc Stock Price Today?
The Vyome Holdings Inc stock price today is 2.115.
What Is the Stock Symbol for Vyome Holdings Inc?
The stock symbol for Vyome Holdings Inc is "HIND."
What Stock Exchange Does Vyome Holdings Inc Trade On?
Vyome Holdings Inc is listed and trades on the NASDAQ stock exchange.
Is Vyome Holdings Inc a Good Stock to Buy?
Determining whether Vyome Holdings Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the HIND quote. (ISIN: US92943X1046)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.010
2.139
52 wk Range
1.750
18.600
Earnings results expected in 10 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.0102.139
52 wk Range
1.75018.600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
HIND Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
11.500
Upside
+443.74%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Vyome gets Chinese patent for besifloxacin acne gel- Investing.com
- Vyome gets Chinese patent for besifloxacin acne gel
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.500
(+443.74% Upside)
Vyome Holdings Inc Earnings Call Summary for Q1/2026
- Cash reserves surged to $8.8M from $5.0M prior quarter; company maintains zero debt and posted $963K net loss ($0.15/share) in Q1 2026.
- Lead program VT-1953 for malignant fungating wounds advances toward pivotal trials with ongoing FDA regulatory engagement and submissions.
- Strategic in-licensing deal with Impetis Biosciences secured JAK inhibitor assets with no upfront or milestone payments required.
- Stock declined 84% from 52-week high to $2.27; management pursues non-dilutive funding for JAK program over next 12-24 months.
- Q1 operating expenses totaled $1.15M with R&D comprising 57.4%; CEO emphasizes disciplined capital allocation and shareholder value focus.
Last Updated: 06/04/2026, 12:06 AM
Read Full TranscriptEarnings
Latest Release
May 28, 2026
EPS / Forecast
-0.15 / -0.10
Revenue / Forecast
31.59K / --
Compare HIND to Peers and Sector
Metrics to compare | HIND | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHINDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.4x | −2.6x | −0.4x | |
PEG Ratio | - | −0.21 | 0.00 | |
Price/Book | 2.2x | 3.7x | 2.6x | |
Price / LTM Sales | 97.2x | 3.6x | 3.0x | |
Upside (Analyst Target) | - | 52.1% | 56.0% | |
Fair Value Upside | Unlock | 9.3% | 9.1% | Unlock |
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Vyome Holdings (HIND) Stock Price Today?
The Vyome Holdings stock price today is 2.115 USD.
What Stock Exchange Does Vyome Holdings Trade On?
Vyome Holdings is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Vyome Holdings?
The stock symbol for Vyome Holdings is "HIND."
What Is the Vyome Holdings Market Cap?
As of today, Vyome Holdings market cap is 14.840M USD.
What Is Vyome Holdings's Earnings Per Share (TTM)?
The Vyome Holdings EPS (TTM) is -2.851.
When Is the Next Vyome Holdings Earnings Date?
Vyome Holdings will release its next earnings report on Aug 13, 2026.
From a Technical Analysis Perspective, Is HIND a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Vyome Holdings Stock Split?
Vyome Holdings has split 11 times.
How Many Employees Does Vyome Holdings Have?
Vyome Holdings has 14 employees.
What is the current trading status of Vyome Holdings (HIND)?
As of Aug 03, 2026, Vyome Holdings (HIND) is trading at a price of 2.115 USD, with a previous close of 2.115 USD. The stock has fluctuated within a day range of 2.010 USD to 2.139 USD, while its 52-week range spans from 1.750 USD to 18.600 USD.
What Is Vyome Holdings (HIND) Price Target According to Analysts?
The average 12-month price target for Vyome Holdings is 11.500 USD, with a high estimate of 15 USD and a low estimate of 8 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +443.74% Upside potential.
What Is the HIND After Hours Price?
HIND's last after hours stock price is 2.130 USD, the stock has decreased by 0.015, or 0.700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.